Download Files:
Products Details
Product Description
– 3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor[1][2]. 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A shows anti-orthopoxvirus activity[6][7].
Web ID
– HY-10442
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Molecular Formula
– C12H14N4O3
Citations
– Cancers (Basel). 2022 Jul 23;14(15):3600.|Cell Death Dis. 2020 Oct 23;11(10):906.|Cell Rep. 2023 May 23;42(6):112550.|Cell Reprogram. 2017 Dec;19(6):363-371.|Cells Tissues Organs. 2021 Jan 18;1-9.|Int Immunopharmacol. 2022 Feb 19;106:108612.|J Am Soc Nephrol. 2016 Jul;27(7):2021-34. |J Immunother Cancer. 2019 Nov 14;7(1):300. |J Mol Cell Cardiol. 2019 Oct;135:119-133.|Lab Invest. 2021 Mar 10.|Nat Commun. 2021 Feb 23;12(1):1237.|Patent. US20180263995A1.|Research Square Preprint. 2020 May.|Research Square Print. September 13th, 2022.|Apoptosis. 2020 Oct;25(9-10):697-714.|Biochem Biophys Res Commun. 2018 Sep 10;503(3):2061-2067.|bioRxiv. 2023 Apr 21.|Exp Mol Pathol. 2020 Feb;112:104344.|J Pharmacol Exp Ther. 2019 Sep;370(3):490-503.|Nat Commun. 2022 Jan 10;13(1):12.|Università degli Studi di CAGLIARI. Dipartimento di Scienze Biomediche. 2021 May.
References
– [1]Siddiqi FS, et al. The Histone Methyltransferase Enzyme Enhancer of Zeste Homolog 2 Protects against Podocyte Oxidative Stress and Renal Injury in Diabetes. J Am Soc Nephrol. 2016 Jul;27(7):2021-34.|[2]Avan A, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012 Aug;11(8):1735-46.|[3]Sun F, et al. Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus?. Eur J Pharm Sci. 2015 Sep 18;77:290-302.|[4]Kikuchi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012 Nov;78(2):138-43.|[5]Fiskus W, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 2009, 114(13), 2733-2743.|[6]Noriko Uchiyama, et al. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a. Eur J Pharmacol. 2017 Oct 5;812:138-146.|[7]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52.
CAS Number
– 102052-95-9
Molecular Weight
– 262.26
Compound Purity
– 98.12
SMILES
– O[C@@H]1[C@H](O)C(CO)=C[C@H]1N2C=NC3=C2C=CN=C3N
Clinical Information
– No Development Reported
Research Area
– Cancer; Infection
Solubility
– 10 mM in DMSO
Target
– Histone Methyltransferase;Orthopoxvirus
Isoform
– EZH2
Pathway
– Anti-infection;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
